Compare Howmet Aerospace Inc (HWM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs BIO-TECHNE Corp — how do they compare? Howmet Aerospace Inc trades at $278.54 (market cap $108.82B), while BIO-TECHNE Corp trades at $71.58 (market cap $11.16B). The key difference: Howmet Aerospace Inc is far larger — about 9.8× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.45%). Which is the better fit depends on your goals.
| HWM | TECH | |
|---|---|---|
Market Cap | $108.82B | $11.16B |
Sector | Industrials | Health |
52-Week High | $283.23 | $72.12 |
52-Week Low | $171.00 | $43.31 |
Enterprise Value | $111.07B | $11.24B |
Dividend Yield | 0.18% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $271.98, down 0.17% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.22 exceeding the $1.11 estimate. Financials show robust profitability, including a 20.22% net income margin and 33.98% ROE, though valuation ratios like a P/E of 63.21 appear elevated. Recent news highlights commercial aerospace demand driving growth, with shares gaining 249% since May 2024 according to FXEmpire on July 15, 2026.
The outlook remains positive due to sustained aerospace demand and analyst consensus favoring buys, but risks include high valuation sensitivity and market volatility. Upside to the $317.63 price target offers potential, yet investors should weigh premium multiples against earnings growth momentum and sector cyclicality.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
